Last $2.42 USD
Change Today -0.10 / -3.97%
Volume 83.3K
OCLS On Other Exchanges
Symbol
Exchange
OCLS is not on other exchanges.
As of 5:20 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1129 North McDowell Boulevard

Petaluma, CA 94954

United States

Phone: 707-283-0550

Fax: 707-283-0551

Oculus Innovative Sciences, Inc., a healthcare company, designs, produces, and markets prescription and non-prescription products in approximately 20 countries. The company focuses on products for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets. The company’s primary focus is on the commercialization of its proprietary technology platform called Microcyn Technology. This technology is based on electrically charged oxychlorine small molecules designed to target a range of organisms that cause disease (pathogens). These organisms include viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, as well as Clostridium difficile, a contagious bacteria spread by human contact. Various Microcyn Technology tissue care products are designed to treat infections and improve healing while reducing the need for antibiotics. Outside the United States, the company’s Microcyn Technology products have a European Conformity mark, known as a Conformité Européenne Mark, device approval in Europe for debriding, irrigating, and moistening acute and chronic wounds in wound treatment through local antimicrobial effect in the wound bed and creating a moist environment. In 2013, the company was granted a Mexican patent for the use of its novel antimicrobial surgical solution in the treatment and prevention of peritonitis. In India, the company’s technology has a drug license for cleaning and debriding in wound management. In China, it has obtained a medical device approval by the State Food and Drug Administration for reducing the propagation of microbes in wounds and creating a moist environment for wound healing. Microcyn Technology Platform Microcyn Technology’s ability to reduce the need for antibiotics through prevention and treatment of infections while promoting wound healing is based on its engineered chemistry. As a result of the company’s patented manufacturing process, Microcyn is a proprietary solution of oxychlorine compounds that interact with and inactivate surface proteins on cell walls and membranes of microorganisms. The functions of these proteins are varied and play major roles in cell communication, nutrient and waste transport and other required functions for cell viability. Once Microcyn surrounds single cell microorganisms, it damages these proteins, causing the cell membrane to rupture, leading to cell death. The company has completed a proof-of-concept Phase II trial in the United States, which demonstrated the effectiveness of Microcyn Technology in mildly infected diabetic foot ulcers with the primary endpoint of clinical cure and improvement of infection. Sales and Marketing The company sells its products in the United States through partners and its direct sales force, and internationally through strategic business partners. In the United States, the company sells into acute/wound care markets with its dedicated contract sales force, the dermatology markets through its partner, Quinnova Pharmaceuticals, Inc.; and into animal healthcare and over-the-counter wound care markets through Innovacyn, Inc. In the international markets, it works with partners, ranging from country specific distributors to a primary pharmaceutical company to a full service sales and marketing company. The company’s products are primarily purchased by hospitals, physicians, nurses, other healthcare practitioners, and others who are the primary caregivers to patients, both human and animal, being treated for acute or chronic wounds or undergoing surgical procedures, as well as to dermatologists for treatment of various skin afflictions. Intellectual Property As of June 2014, the company owned a total of 31 issued patents, including 5 issued U.S. patents and 26 issued foreign patents. It also has 93 pending U.S. and foreign patent applications that include various PCT applications. Three of the patent applications (two U.S. applications and one PCT application) are directed to chlorogenic acid. The remaining patent applications, as well as the issued patents are directed at it

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCLS:US $2.42 USD -0.10

OCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,498 JPY -25.00
Henry Schein Inc $119.69 USD +0.24
Integra LifeSciences Holdings Corp $49.99 USD +0.33
Patterson Cos Inc $40.27 USD -0.05
Smith & Nephew PLC 1,043 GBp -11.00
View Industry Companies
 

Industry Analysis

OCLS

Industry Average

Valuation OCLS Industry Range
Price/Earnings 3.4x
Price/Sales 1.5x
Price/Book 1.6x
Price/Cash Flow 4.0x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit www.oculusis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.